 |
|
|
| |
Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-G2 or G3 patients: SVR12 results from VITAL-1 Phase 2b study
|
| |
| |
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
JM Pawlotsky1, SK Sarin2, GR Foster3 CY Peng4,
J Rasenack5, R Flisiak6, T Piratvisuth7, H Wedemeyer8,
WL Chuang9, WM Zhang10, NV Naoumov11
1Hôpital Henri Mondor, Créteil, France; 2Department of Gastroenterology, G B Pant Hospital, Delhi, India; 3Queen Mary's University of London, Bart's and The London School of Medicine, London, UK; 4China Medical University Hospital, Chinese Medical University, Taichung, Taiwan; 5Albert Ludwigs University, Freiburg, Germany; 6Medical University, Bialystok, Poland; 7NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand; 8Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany; 9Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 10Beijing Novartis Pharma Co. Ltd., Shanghai, China; 11Novartis Pharma AG, Basel, Switzerland
|
| |
|
|
|
|
|
